TransMedics Group, Inc. (TMDX) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Devices secteur d'activité. Le siège social de l'entreprise est situé à Andover, MA, United States. Le PDG actuel est Waleed H. Hassanein.
TMDX a date d'introduction en bourse 2019-05-02, 728 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $3.98B.
TransMedics Group, Inc. is a commercial-stage medical technology company headquartered in Andover, Massachusetts, focused on transforming organ transplant therapy for end-stage organ failure patients globally. The company develops and commercializes the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring platform that uses proprietary technology to maintain near-physiologic conditions for donor organs outside the human body. Its product portfolio includes OCS LUNG for lung preservation, OCS Heart for cardiac preservation, and OCS Liver for hepatic preservation, each designed to improve transplant outcomes and expand the pool of viable organs. Founded in 1998, TransMedics addresses critical challenges in organ transplantation through innovative ex vivo organ preservation technology.
